| 2.18 0.11 (5.31%) | 08-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.91 | 1-year : | 3.3 |
| Resists | First : | 2.49 | Second : | 2.82 |
| Pivot price | 2.14  |
|||
| Supports | First : | 1.95 | Second : | 1.62 |
| MAs | MA(5) : | 2.06 |
MA(20) : | 2.22 |
| MA(100) : | 2.44 |
MA(250) : | 2.28 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 12.7 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 3.81 | Low : | 1.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CNTB ] has closed below upper band by 42.7%. Bollinger Bands are 31.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.22 - 2.23 | 2.23 - 2.24 |
| Low: | 2.04 - 2.05 | 2.05 - 2.06 |
| Close: | 2.16 - 2.18 | 2.18 - 2.19 |
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Fri, 31 Jul 2026
CNTB|Connect Biopharma Holdings Ltd|Price:2.020|Chg%:-0.070 - TradingKey
Fri, 31 Jul 2026
CNTB|Connect Biopharma Holdings Ltd|Price:2.020|Chg%:-0.070 - TradingKey
Sat, 25 Jul 2026
Connect Biopharma Holdings Limited Revenue Breakdown – NASDAQ:CNTB - TradingView
Thu, 23 Jul 2026
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent (NASDAQ:CNTB) - Seeking Alpha
Mon, 29 Jun 2026
Connect Biopharma Holdings Limited(NasdaqGM: CNTB) added to Russell 2000 Index - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 1.885e+007 (%) |
| Held by Institutions | 31.8 (%) |
| Shares Short | 1,060 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.554e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -11 % |
| Return on Assets (ttm) | 601.7 % |
| Return on Equity (ttm) | -54.3 % |
| Qtrly Rev. Growth | 233000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.06e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|